Dan Aderka

12.3k total citations · 2 hit papers
122 papers, 5.5k citations indexed

About

Dan Aderka is a scholar working on Oncology, Immunology and Surgery. According to data from OpenAlex, Dan Aderka has authored 122 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 30 papers in Immunology and 22 papers in Surgery. Recurrent topics in Dan Aderka's work include Colorectal Cancer Treatments and Studies (13 papers), Immune Response and Inflammation (11 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Dan Aderka is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Immune Response and Inflammation (11 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Dan Aderka collaborates with scholars based in Israel, United States and United Kingdom. Dan Aderka's co-authors include David Wallach, Hartmut Engelmann, Cord Brakebusch, Junming Le, J Vilček, ‪Yasmin Maor‬‏, M.W. Greaves, R.D.R. Camp, Y Levo and Menachem Rubinstein and has published in prestigious journals such as The Lancet, JAMA and Journal of Biological Chemistry.

In The Last Decade

Dan Aderka

118 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.

1992 705 citations Dan Aderka, Hartmut Engelmann et al. The Journal of Experimental Medicine profile →
IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice.

1989 512 citations Dan Aderka et al. profile →

Peers

Countries citing papers authored by Dan Aderka

Since Specialization

Citations

This map shows the geographic impact of Dan Aderka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Aderka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Aderka more than expected).

Fields of papers citing papers by Dan Aderka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Aderka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Aderka. The network helps show where Dan Aderka may publish in the future.

Co-authorship network of co-authors of Dan Aderka

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Aderka. A scholar is included among the top collaborators of Dan Aderka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Aderka. Dan Aderka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma 2023 ·Cancer Investigation ·Ofer Margalit, (unknown), Einat Shacham‐Shmueli, (unknown), Yu‐Xiao Yang, Yaacov Richard Lawrence, (unknown), Idan Levy, Kim A. Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce J. Giantonio, Ronac Mamtani, Ben Boursi	1
2	Repeat Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Recurrences is Safe and Efficacious 2021 ·Annals of Surgical Oncology ·Shachar Laks, (unknown), Mohammad Adileh, Almog Ben‐Yaacov, Ofer Purim, (unknown), Dan Aderka, Einat Shacham‐Shmueli, Naama Halpern, (unknown), (unknown), Aviram Nissan	10
3	SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC 2021 ·Annals of Oncology ·Dan Aderka, Scott Kopetz, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, (unknown), Adrian Edwards, Josep Tabernero	5
4	Perioperative and Oncological Outcomes of Combined Hepatectomy with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer 2020 ·Annals of Surgical Oncology ·Mohammad Adileh, Eyal Mor, Dan Assaf, (unknown), Shachar Laks, Almog Ben‐Yaacov, (unknown), David Hazzan, Einat Shacham‐Shmueli, Ofer Margalit, Naama Halpern, Dan Aderka, (unknown), Arié Ariche, Aviram Nissan	7
5	Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies 2019 ·The Lancet Oncology ·Dan Aderka, Sebastian Stintzing, Volker Heinemann	40
6	A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification—Defining novel predictive and prognostic markers in stage III colon cancer 2018 ·European Journal of Cancer ·Ofer Margalit, Ronac Mamtani, Yu‐Xiao Yang, Kim A. Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce J. Giantonio, Einat Shacham‐Shmueli, Ben Boursi	6
7	Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer 2018 ·European Journal of Cancer ·Ofer Margalit, Ronac Mamtani, Yu‐Xiao Yang, Kim A. Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce J. Giantonio, Einat Shacham‐Shmueli, Ben Boursi	32
8	Resilience and Psychosocial Adjustment in Digestive System Cancer 2015 ·Journal of Clinical Psychology in Medical Settings ·(unknown), Miri Cohen, Hasida Ben‐Zur, Einat Shacham‐Shmueli, Dan Aderka, Nava Siegelmann‐Danieli, Alex Beny	32
9	Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers 2014 ·British Journal of Cancer ·Talia Golan, Zaheer Kanji, Ron Epelbaum, (unknown), Efrat Dagan, Spring Holter, Dan Aderka, Shani Paluch–Shimon, Brett A. Kaufman, Ruth Gershoni‐Baruch, David W. Hedley, Malcolm J. Moore, Eitan Friedman, Steven Gallinger	311
10	Curcumin Augments Gemcitabine Cytotoxic Effect on Pancreatic Adenocarcinoma Cell Lines 2007 ·Cancer Investigation ·Shahar Lev‐Ari, Akiva Vexler, Alex Starr, (unknown), Joel Greif, Dan Aderka, Rami Ben‐Yosef	95
11	2133 2006 ·International Journal of Radiation OncologyBiologyPhysics ·Zvi Symon, Tatiana Rabin, (unknown), (unknown), D. Alezra, Theodore S. Lawrence, Dan Aderka, Ido Wolf, Raphael Catane, M. Raphael Pfeffer	4
12	Soluble Tumor Necrosis Factor Receptor Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Interleukin-2-Based lmmunotherapy 1993 ·Journal of Immunotherapy ·Arie S. Belldegrun, William Pierce, D. Sayah, Jean B. deKernion, David Wallach, Dan Aderka, Robert A. Figlin	11
13	Erythropoietin Therapy Obviates the Need for Recurrent Transfusions in a Patient with Severe Hemolysis due to Prosthetic Valves 1992 ·CHEST Journal ·Ran Kornowski, (unknown), (unknown), Amos Pines, Dan Aderka, Y Levo	8
14	Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. breakdown → 1992 ·The Journal of Experimental Medicine ·Dan Aderka, Hartmut Engelmann, ‪Yasmin Maor‬‏, Cord Brakebusch, David Wallach	705
15	Budd–Chiari Syndrome in Israel: Predisposing Factors, Prognosis, and Early Identification of High-Risk Patients 1991 ·Journal of Clinical Gastroenterology ·Mordechai Averbuch, Dan Aderka, (unknown), Y Levo	3
16	Does tumor necrosis factor play a role in the pathogenesis of fulminant hepatitis? 1988 ·Medical Hypotheses ·Dan Aderka, Y Levo	6
17	Recombinant interferon alpha-C for advanced hairy cell leukemia. An Israeli multicenter study 1988 ·Cancer ·Dan Aderka, Rita Michalevicz, Yair Daniel, Y Levo, (unknown), Isaac Ben‐Bassat, Bracha Ramot, (unknown), Miron Prokocimer, A. Berrebi, Dina Meytes, Hanna Rosenbaum, David Wallach, Michel Revel	5
18	Sensitizing effects and mechanisms of desensitization in regulation of the in vivo response to TNF 1988 ·Annales de l Institut Pasteur Immunologie ·David Wallach, Helmut Holtmann, Dan Aderka, Talia Hahn, Hartmut Engelmann, Y. Nophar	1
19	Life-Threatening Theophylline Intoxication in a Hypothyroid Patient 1983 ·Respiration ·Dan Aderka, (unknown), Doron Garfinkel, M Santo, S. Gitter, J Pinkhas	6
20	Inadvertently induced hypoglycemia. 1978 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Dan Aderka, J Pinkhas	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact